Breo Ellipta clinical uses
Pro Research Analysisby 
Searched over 200M research papers
Breo Ellipta Clinical Uses: COPD and Asthma Treatment
Chronic Obstructive Pulmonary Disease (COPD) Indications
Breo Ellipta, a combination of fluticasone furoate (an inhaled corticosteroid) and vilanterol (a long-acting beta-2 agonist), is widely approved and used for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including those with chronic bronchitis and/or emphysema 12458. It is also indicated to reduce the frequency of COPD exacerbations in patients with a history of such events 245. Clinical studies have shown that Breo Ellipta provides rapid and sustained improvements in lung function, reduces exacerbation rates, and is generally well tolerated. Its once-daily dosing may improve adherence compared to twice-daily alternatives 45.
Asthma Indications
Breo Ellipta is also approved for the treatment of asthma in adults and adolescents for whom a combination of an inhaled corticosteroid and a long-acting beta-2 agonist is appropriate 367. The medication is available in two strengths (100/25 mcg and 200/25 mcg) and is administered once daily using the Ellipta dry powder inhaler . Clinical trials have demonstrated that Breo Ellipta improves pulmonary function, reduces the risk of severe asthma exacerbations, and enhances asthma control and quality of life. Its efficacy is comparable to other fixed ICS/LABA combinations that require twice-daily dosing, offering the added convenience of once-daily administration .
Safety and Tolerability
Breo Ellipta is generally well tolerated in both COPD and asthma patients, with a safety profile similar to its individual components and other combination inhalers. However, as with other inhaled corticosteroids, there is an increased risk of pneumonia with long-term use in COPD patients . Systemic side effects are minimal due to low systemic exposure when administered via inhalation .
Conclusion
Breo Ellipta is an effective, once-daily inhaled therapy for both COPD and asthma, offering improvements in lung function, reduction in exacerbations, and the potential for better treatment adherence due to its convenient dosing schedule 12345678.
Sources and full results
Most relevant research papers on this topic